GSK signs $43 million AI-based drug discovery deal with Exscientia

06:26 EDT 3 Jul 2017 | Pharmafile

With AI partnerships becoming increasingly common in the life sciences industry, it has emerged that GSK is to partner up with Scottish firm Exscientia in a $43 million deal in a bid to utilise the latter’s AI-driven platform to supercharge and streamline its drug discovery business.  

read more

Original Article: GSK signs $43 million AI-based drug discovery deal with Exscientia


More From BioPortfolio on "GSK signs $43 million AI-based drug discovery deal with Exscientia"

Quick Search


Relevant Topics

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.

GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...